Pluristem Therapeutics Stock News

Pluristem Therapeutics (NASDAQ:PSTI) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability. Analyst Ratings This is a summary of current ratings and recommmendations for Pluristem Therapeutics and Sana []

Zacks Investment Research upgraded shares of Pluristem Therapeutics (NASDAQ:PSTI) from a sell rating to a buy rating in a report issued on Friday morning, Zacks.com reports. Zacks Investment Research currently has $3.00 target price on the biotechnology companys stock. According to Zacks, PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized []

JPMorgan Chase & Co. cut its holdings in shares of Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 46.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,761 shares of the biotechnology companys stock after selling 34,680 shares during the quarter. JPMorgan Chase & []

JPMorgan Chase & Co. reduced its position in Pluristem Therapeutics Inc. (NASDAQ:PSTI) by 46.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,761 shares of the biotechnology companys stock after selling 34,680 shares during the quarter. JPMorgan Chase & Co. []

Pluristem Therapeutics (NASDAQ:PSTI) and Axcella Health (NASDAQ:AXLA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk. Volatility & Risk Pluristem Therapeutics has a beta of 2.25, indicating that its stock price []

Having recruited patients in the U.S., Europe and Israel, the Company anticipates topline results in the third calendar quarter of 2022

Having recruited patients in the U.S., Europe and Israel, t he Company anticipates topline results in the third calendar quarter of 2022

HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief Ex

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. V

HAIFA, Israel, July 08, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company announced today that it is bringing its Acut

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold nearly 194,000 shares of Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc (NASDAQ: PSTI) has received €20 million (approximately $24 million) from the European Investment Bank (EIB), the first disbursement of three tranches of funding. The d

The stock price of Pluristem Therapeutics Inc. (NASDAQ: PSTI) increased from $4.52 to over $4.90 pre-market. This is why it happened.

Longeveron Seeks $25 Million IPO For Anti-Aging Efforts

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic pr